Extracorporeal Membrane Oxygenation Machine Market by Device Type (Veno Arterial, Veno Venous), Component Type (Cannula, Controllers, Heat Exchangers), Patient Type, Application, End User - Global Forecast 2025-2032
Description
The Extracorporeal Membrane Oxygenation Machine Market was valued at USD 551.20 million in 2024 and is projected to grow to USD 579.25 million in 2025, with a CAGR of 5.40%, reaching USD 840.14 million by 2032.
A concise, authoritative primer that frames contemporary clinical drivers and operational imperatives shaping extracorporeal membrane oxygenation adoption across care settings
Extracorporeal membrane oxygenation (ECMO) is increasingly central to advanced cardiopulmonary care pathways, providing life-sustaining support when conventional therapies are insufficient. Clinical teams are employing ECMO across a widening range of acute indications, from refractory respiratory failure to complex cardiac support scenarios, and the technology ecosystem that enables safe, reliable extracorporeal circulation has matured significantly. In parallel, healthcare delivery settings are integrating ECMO capabilities beyond tertiary centers, prompting a re-evaluation of device design, training requirements, and system-level readiness.
In response to these shifts, industry stakeholders are prioritizing device modularity, simplified user interfaces, and interoperable components that reduce setup time and procedural complexity. Equipment manufacturers and clinical leaders are collaborating to align technology with emergent protocols in extracorporeal cardiopulmonary resuscitation and perioperative cardiac care. Consequently, procurement and clinical governance processes must adapt to balance clinical benefits with operational implications such as consumable logistics, maintenance schedules, and competency-based staffing models.
This report synthesizes contemporary evidence and market signals to inform strategic decision-making for clinicians, hospital executives, and device suppliers. It emphasizes practical considerations, regulatory dynamics, and innovation vectors likely to shape ECMO deployment across varied care environments.
How device miniaturization, interoperable controls, and standardized training are collectively reshaping clinical adoption pathways and supply strategies in ECMO care
The ECMO landscape is experiencing several transformative shifts that are redefining clinical pathways and supplier strategies. Advances in miniaturized pump technology and improved oxygenator biocompatibility have reduced procedural complexity and device-associated complications, which in turn expands the pool of clinicians and centers qualified to deliver extracorporeal support. Concurrently, software-driven controllers and enhanced sensor integration are enabling better hemodynamic monitoring and automated safety features, which improve clinical confidence during transport and prolonged support.
Another significant change is the movement toward standardized training curricula and competency frameworks that facilitate safer decentralization of ECMO services. As clinical guidelines evolve, interdisciplinary teams are refining patient selection criteria and post-decannulation care, which affects resource allocation and care pathways. In parallel, supply chain resilience has become a strategic priority: manufacturers are revisiting sourcing strategies and aftermarket support to reduce downtime and ensure continuity of care.
Taken together, these shifts demand that health systems, clinical leaders, and device developers adopt a systems-thinking approach, aligning technology investments with workforce development and operational resilience. This alignment is crucial to translate technological advances into consistent clinical outcomes and sustainable service models.
Impacts of 2025 tariff measures on component sourcing, procurement timelines, and strategic vendor alignment affecting ECMO supply continuity and cost stability
Tariff policy enacted in 2025 introduced a new layer of complexity into the procurement and supply strategies for ECMO devices and components, prompting immediate reassessments across stakeholders. Import tariffs on selected medical device categories affected the landed cost of key components such as oxygenators and pumps, compelling manufacturers and distributors to revisit sourcing arrangements, contract terms, and inventory buffers. In response, several suppliers accelerated diversification of their supplier base, intensified negotiations with domestic subcontractors, and explored regional manufacturing agreements to mitigate exposure to cross-border tariff volatility.
Healthcare providers reacted by re-evaluating procurement timelines and contracting practices. Longer lead times and elevated acquisition costs influenced prioritization of purchases and pushed some organizations toward multi-year service agreements that lock in maintenance and consumable supply at agreed rates. In some instances, clinical teams and supply chain leaders elected to standardize on devices with stronger local support footprints to reduce logistical risk and ensure timely access to consumables and technical service.
Overall, the tariff environment reinforced the importance of scenario planning and contract flexibility. Health systems that combined proactive vendor engagement with contingency inventory strategies and close clinical-supply chain collaboration demonstrated greater continuity of care and cost predictability during the transitional period.
Detailed segmentation analysis revealing how device architecture, component portfolios, patient cohorts, clinical applications, and end-user settings drive differentiated strategies
Segmentation insights reveal differentiated dynamics across device architectures, component portfolios, patient cohorts, applications, and care settings that are essential for strategic positioning. Based on device type, practitioners distinguish between Veno Arterial systems optimized for combined cardiac and pulmonary support and Veno Venous systems tailored primarily for respiratory failure, with each architecture driving distinct clinical training needs and perfusion strategies. Based on component type, the ecosystem includes cannula, controllers, heat exchangers, oxygenators, and pumps, and competitive advantage often hinges on the integration and reliability of these subcomponents as well as consumable lifecycle management. Based on patient type, adults, infants, and pediatric populations present divergent physiological considerations, cannulation strategies, and device sizing requirements that influence design priorities and clinician education programs.
Based on application, clinical deployment spans cardiac support, extracorporeal cardiopulmonary resuscitation, and respiratory support, and within cardiac support there is further focus on cardiogenic shock and post cardiotomy scenarios, each with unique timing, monitoring, and weaning protocols. Based on end user, ambulatory surgical centers, hospitals, and specialty clinics exhibit distinct operational constraints: ambulatory settings emphasize rapid turnover and portability, hospitals balance intensive care capacity with multidisciplinary teams, and specialty clinics prioritize niche expertise and high-touch follow-up care. Taken together, these segmentation layers shape product roadmaps, training investments, and aftermarket services that suppliers must tailor to meet heterogeneous clinical and operational needs.
How regional healthcare systems and infrastructure differences are influencing ECMO adoption patterns, supplier strategies, and localized support models across global markets
Regional dynamics are shaping where and how ECMO capabilities expand, with distinct opportunities and constraints across global geographies. In the Americas, established tertiary centers continue to drive clinical innovation and the decentralization of services into regional hospitals, supported by robust training networks and integrated critical care systems. In Europe, Middle East & Africa, heterogeneity across healthcare infrastructures creates mixed adoption patterns: high-resource centers lead in clinical protocol development while emerging markets focus on scalable, cost-conscious solutions and capacity building. In the Asia-Pacific region, rapid investment in critical care infrastructure and an increasing number of specialized centers have fostered strong demand for adaptable device configurations and localized support ecosystems.
Across all regions, regulatory frameworks, reimbursement mechanisms, and workforce capacity influence adoption timelines and supplier strategies. In response, manufacturers are tailoring market entry plans, establishing regional support hubs, and collaborating with clinical partners to develop context-specific training and service models. These regional adaptations are essential for ensuring that device performance, aftermarket logistics, and clinical education align with local standards and operational realities, thereby enabling safe and sustained ECMO delivery.
Competitive landscape insights highlighting how platform modularity, component innovation, and service ecosystems are shaping supplier differentiation and clinical partnerships
Competitive dynamics in the ECMO ecosystem reflect a mix of established medical device manufacturers, specialized component suppliers, and emerging technology entrants. Leading device makers are investing in modular platforms that prioritize user ergonomics, quicker priming procedures, and enhanced monitoring capabilities while also expanding service networks to provide faster technical support and consumable availability. Component specialists are differentiating through materials science innovations in oxygenator membranes and pump technologies that aim to reduce hemolysis and thrombogenicity, thereby improving patient safety and durability of support.
Simultaneously, new entrants are leveraging software, sensor fusion, and telemedicine-enabled oversight to address clinician support and remote troubleshooting, which can be particularly valuable for centers expanding ECMO services without long-standing in-house expertise. Strategic partnerships and licensing agreements between platform manufacturers and component innovators are increasingly common, enabling integrated solutions that combine proven hardware with advanced monitoring and analytics. For health systems, supplier selection is increasingly informed not only by device performance but also by the quality of training programs, responsiveness of technical service, and the ecosystem’s capacity to support lifecycle management and clinical outcomes.
Actionable strategic priorities for organizations to align procurement, training, and supply resilience for scalable and sustainable ECMO program expansion
Industry leaders should adopt a multifaceted strategy that aligns technology selection with workforce development, supply chain resilience, and clinical governance to maximize the impact of ECMO adoption. First, prioritize procurement decisions that evaluate device interoperability and the availability of comprehensive training programs, because devices that facilitate consistent clinician performance will reduce variability in outcomes and operational disruption. Second, negotiate contracts that include reliable consumable supply arrangements and service-level commitments, since continuity of supply and timely maintenance are critical to sustain high-acuity services.
Third, invest in structured training and competency assessment frameworks that integrate simulation-based learning with on-the-job mentorship to accelerate safe program expansion. Fourth, develop cross-functional governance structures that bring together clinical leadership, supply chain, and biomedical engineering to manage device selection, inventory planning, and escalation procedures. Fifth, incorporate scenario planning into capital and operational planning to address tariff fluctuations, supplier disruptions, and emergent clinical demand. By implementing these recommendations, organizations can reduce deployment risk, improve clinical outcomes, and create a scalable foundation for responsible ECMO service growth.
Transparent and reproducible research approach combining expert interviews, technical analysis, and regulatory review to validate clinical and operational findings
This research synthesizes primary interviews with clinicians, biomedical engineers, and supply chain leaders alongside secondary review of peer-reviewed literature, regulatory documents, and technical specifications to construct a comprehensive view of device and service dynamics. Primary qualitative insights were gathered through structured interviews and expert panels to capture operational challenges, clinical use-case nuances, and supplier performance attributes. Secondary sources were evaluated to validate technical claims regarding device components, biocompatibility improvements, and controller functionalities, ensuring alignment with current standards of care.
Analytic methods included comparative device feature mapping, component reliability assessment, and scenario analysis for procurement and supply-chain contingencies. Where applicable, regulatory filings and clinical guideline updates were reviewed to understand approval trajectories and recommended practice changes. Triangulation across multiple data streams ensured consistency of findings and highlighted areas of consensus and divergence among clinical and operational stakeholders. The methodology emphasizes transparency, reproducibility, and alignment with evidence-based clinical practice to support informed decision-making by technology buyers and clinical leaders.
A decisive synthesis that underscores the need for aligned investments in devices, training, and supply resilience to enable safe and sustainable ECMO service growth
In conclusion, ECMO technology and service delivery are at an inflection point where device innovation, workforce training, and supply chain strategy must converge to enable safe, scalable adoption. Advances in component design and controller intelligence are lowering procedural barriers, while evolving clinical protocols and competency frameworks are enabling broader use across care settings. At the same time, external forces such as tariff shifts and regional infrastructure differences underscore the need for flexible procurement strategies and stronger supplier partnerships.
For clinical leaders and executives, the imperative is clear: align capital investments with structured training programs, prioritize vendors that offer robust aftermarket support, and embed contingency planning into procurement processes. When these elements are coordinated, institutions can safely expand extracorporeal capabilities, improve patient outcomes, and create resilient services that adapt to regulatory and supply-side volatility. The path forward requires integrated planning, continuous clinician engagement, and disciplined operational governance to translate technological promise into consistent clinical benefit.
Please Note: PDF & Excel + Online Access - 1 Year
A concise, authoritative primer that frames contemporary clinical drivers and operational imperatives shaping extracorporeal membrane oxygenation adoption across care settings
Extracorporeal membrane oxygenation (ECMO) is increasingly central to advanced cardiopulmonary care pathways, providing life-sustaining support when conventional therapies are insufficient. Clinical teams are employing ECMO across a widening range of acute indications, from refractory respiratory failure to complex cardiac support scenarios, and the technology ecosystem that enables safe, reliable extracorporeal circulation has matured significantly. In parallel, healthcare delivery settings are integrating ECMO capabilities beyond tertiary centers, prompting a re-evaluation of device design, training requirements, and system-level readiness.
In response to these shifts, industry stakeholders are prioritizing device modularity, simplified user interfaces, and interoperable components that reduce setup time and procedural complexity. Equipment manufacturers and clinical leaders are collaborating to align technology with emergent protocols in extracorporeal cardiopulmonary resuscitation and perioperative cardiac care. Consequently, procurement and clinical governance processes must adapt to balance clinical benefits with operational implications such as consumable logistics, maintenance schedules, and competency-based staffing models.
This report synthesizes contemporary evidence and market signals to inform strategic decision-making for clinicians, hospital executives, and device suppliers. It emphasizes practical considerations, regulatory dynamics, and innovation vectors likely to shape ECMO deployment across varied care environments.
How device miniaturization, interoperable controls, and standardized training are collectively reshaping clinical adoption pathways and supply strategies in ECMO care
The ECMO landscape is experiencing several transformative shifts that are redefining clinical pathways and supplier strategies. Advances in miniaturized pump technology and improved oxygenator biocompatibility have reduced procedural complexity and device-associated complications, which in turn expands the pool of clinicians and centers qualified to deliver extracorporeal support. Concurrently, software-driven controllers and enhanced sensor integration are enabling better hemodynamic monitoring and automated safety features, which improve clinical confidence during transport and prolonged support.
Another significant change is the movement toward standardized training curricula and competency frameworks that facilitate safer decentralization of ECMO services. As clinical guidelines evolve, interdisciplinary teams are refining patient selection criteria and post-decannulation care, which affects resource allocation and care pathways. In parallel, supply chain resilience has become a strategic priority: manufacturers are revisiting sourcing strategies and aftermarket support to reduce downtime and ensure continuity of care.
Taken together, these shifts demand that health systems, clinical leaders, and device developers adopt a systems-thinking approach, aligning technology investments with workforce development and operational resilience. This alignment is crucial to translate technological advances into consistent clinical outcomes and sustainable service models.
Impacts of 2025 tariff measures on component sourcing, procurement timelines, and strategic vendor alignment affecting ECMO supply continuity and cost stability
Tariff policy enacted in 2025 introduced a new layer of complexity into the procurement and supply strategies for ECMO devices and components, prompting immediate reassessments across stakeholders. Import tariffs on selected medical device categories affected the landed cost of key components such as oxygenators and pumps, compelling manufacturers and distributors to revisit sourcing arrangements, contract terms, and inventory buffers. In response, several suppliers accelerated diversification of their supplier base, intensified negotiations with domestic subcontractors, and explored regional manufacturing agreements to mitigate exposure to cross-border tariff volatility.
Healthcare providers reacted by re-evaluating procurement timelines and contracting practices. Longer lead times and elevated acquisition costs influenced prioritization of purchases and pushed some organizations toward multi-year service agreements that lock in maintenance and consumable supply at agreed rates. In some instances, clinical teams and supply chain leaders elected to standardize on devices with stronger local support footprints to reduce logistical risk and ensure timely access to consumables and technical service.
Overall, the tariff environment reinforced the importance of scenario planning and contract flexibility. Health systems that combined proactive vendor engagement with contingency inventory strategies and close clinical-supply chain collaboration demonstrated greater continuity of care and cost predictability during the transitional period.
Detailed segmentation analysis revealing how device architecture, component portfolios, patient cohorts, clinical applications, and end-user settings drive differentiated strategies
Segmentation insights reveal differentiated dynamics across device architectures, component portfolios, patient cohorts, applications, and care settings that are essential for strategic positioning. Based on device type, practitioners distinguish between Veno Arterial systems optimized for combined cardiac and pulmonary support and Veno Venous systems tailored primarily for respiratory failure, with each architecture driving distinct clinical training needs and perfusion strategies. Based on component type, the ecosystem includes cannula, controllers, heat exchangers, oxygenators, and pumps, and competitive advantage often hinges on the integration and reliability of these subcomponents as well as consumable lifecycle management. Based on patient type, adults, infants, and pediatric populations present divergent physiological considerations, cannulation strategies, and device sizing requirements that influence design priorities and clinician education programs.
Based on application, clinical deployment spans cardiac support, extracorporeal cardiopulmonary resuscitation, and respiratory support, and within cardiac support there is further focus on cardiogenic shock and post cardiotomy scenarios, each with unique timing, monitoring, and weaning protocols. Based on end user, ambulatory surgical centers, hospitals, and specialty clinics exhibit distinct operational constraints: ambulatory settings emphasize rapid turnover and portability, hospitals balance intensive care capacity with multidisciplinary teams, and specialty clinics prioritize niche expertise and high-touch follow-up care. Taken together, these segmentation layers shape product roadmaps, training investments, and aftermarket services that suppliers must tailor to meet heterogeneous clinical and operational needs.
How regional healthcare systems and infrastructure differences are influencing ECMO adoption patterns, supplier strategies, and localized support models across global markets
Regional dynamics are shaping where and how ECMO capabilities expand, with distinct opportunities and constraints across global geographies. In the Americas, established tertiary centers continue to drive clinical innovation and the decentralization of services into regional hospitals, supported by robust training networks and integrated critical care systems. In Europe, Middle East & Africa, heterogeneity across healthcare infrastructures creates mixed adoption patterns: high-resource centers lead in clinical protocol development while emerging markets focus on scalable, cost-conscious solutions and capacity building. In the Asia-Pacific region, rapid investment in critical care infrastructure and an increasing number of specialized centers have fostered strong demand for adaptable device configurations and localized support ecosystems.
Across all regions, regulatory frameworks, reimbursement mechanisms, and workforce capacity influence adoption timelines and supplier strategies. In response, manufacturers are tailoring market entry plans, establishing regional support hubs, and collaborating with clinical partners to develop context-specific training and service models. These regional adaptations are essential for ensuring that device performance, aftermarket logistics, and clinical education align with local standards and operational realities, thereby enabling safe and sustained ECMO delivery.
Competitive landscape insights highlighting how platform modularity, component innovation, and service ecosystems are shaping supplier differentiation and clinical partnerships
Competitive dynamics in the ECMO ecosystem reflect a mix of established medical device manufacturers, specialized component suppliers, and emerging technology entrants. Leading device makers are investing in modular platforms that prioritize user ergonomics, quicker priming procedures, and enhanced monitoring capabilities while also expanding service networks to provide faster technical support and consumable availability. Component specialists are differentiating through materials science innovations in oxygenator membranes and pump technologies that aim to reduce hemolysis and thrombogenicity, thereby improving patient safety and durability of support.
Simultaneously, new entrants are leveraging software, sensor fusion, and telemedicine-enabled oversight to address clinician support and remote troubleshooting, which can be particularly valuable for centers expanding ECMO services without long-standing in-house expertise. Strategic partnerships and licensing agreements between platform manufacturers and component innovators are increasingly common, enabling integrated solutions that combine proven hardware with advanced monitoring and analytics. For health systems, supplier selection is increasingly informed not only by device performance but also by the quality of training programs, responsiveness of technical service, and the ecosystem’s capacity to support lifecycle management and clinical outcomes.
Actionable strategic priorities for organizations to align procurement, training, and supply resilience for scalable and sustainable ECMO program expansion
Industry leaders should adopt a multifaceted strategy that aligns technology selection with workforce development, supply chain resilience, and clinical governance to maximize the impact of ECMO adoption. First, prioritize procurement decisions that evaluate device interoperability and the availability of comprehensive training programs, because devices that facilitate consistent clinician performance will reduce variability in outcomes and operational disruption. Second, negotiate contracts that include reliable consumable supply arrangements and service-level commitments, since continuity of supply and timely maintenance are critical to sustain high-acuity services.
Third, invest in structured training and competency assessment frameworks that integrate simulation-based learning with on-the-job mentorship to accelerate safe program expansion. Fourth, develop cross-functional governance structures that bring together clinical leadership, supply chain, and biomedical engineering to manage device selection, inventory planning, and escalation procedures. Fifth, incorporate scenario planning into capital and operational planning to address tariff fluctuations, supplier disruptions, and emergent clinical demand. By implementing these recommendations, organizations can reduce deployment risk, improve clinical outcomes, and create a scalable foundation for responsible ECMO service growth.
Transparent and reproducible research approach combining expert interviews, technical analysis, and regulatory review to validate clinical and operational findings
This research synthesizes primary interviews with clinicians, biomedical engineers, and supply chain leaders alongside secondary review of peer-reviewed literature, regulatory documents, and technical specifications to construct a comprehensive view of device and service dynamics. Primary qualitative insights were gathered through structured interviews and expert panels to capture operational challenges, clinical use-case nuances, and supplier performance attributes. Secondary sources were evaluated to validate technical claims regarding device components, biocompatibility improvements, and controller functionalities, ensuring alignment with current standards of care.
Analytic methods included comparative device feature mapping, component reliability assessment, and scenario analysis for procurement and supply-chain contingencies. Where applicable, regulatory filings and clinical guideline updates were reviewed to understand approval trajectories and recommended practice changes. Triangulation across multiple data streams ensured consistency of findings and highlighted areas of consensus and divergence among clinical and operational stakeholders. The methodology emphasizes transparency, reproducibility, and alignment with evidence-based clinical practice to support informed decision-making by technology buyers and clinical leaders.
A decisive synthesis that underscores the need for aligned investments in devices, training, and supply resilience to enable safe and sustainable ECMO service growth
In conclusion, ECMO technology and service delivery are at an inflection point where device innovation, workforce training, and supply chain strategy must converge to enable safe, scalable adoption. Advances in component design and controller intelligence are lowering procedural barriers, while evolving clinical protocols and competency frameworks are enabling broader use across care settings. At the same time, external forces such as tariff shifts and regional infrastructure differences underscore the need for flexible procurement strategies and stronger supplier partnerships.
For clinical leaders and executives, the imperative is clear: align capital investments with structured training programs, prioritize vendors that offer robust aftermarket support, and embed contingency planning into procurement processes. When these elements are coordinated, institutions can safely expand extracorporeal capabilities, improve patient outcomes, and create resilient services that adapt to regulatory and supply-side volatility. The path forward requires integrated planning, continuous clinician engagement, and disciplined operational governance to translate technological promise into consistent clinical benefit.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence algorithms for real-time ECMO circuit parameter optimization
- 5.2. Emergence of portable and transportable ECMO systems enabling point-of-care lifesaving interventions
- 5.3. Development of biocompatible polymer coatings to reduce thrombosis in prolonged ECMO support applications
- 5.4. Expansion of venoarterial ECMO utilization in adult cardiogenic shock management and mobile ECMO teams
- 5.5. Advancements in low-resistance hollow fiber oxygenators for improved neonatal and pediatric ECMO outcomes
- 5.6. Regulatory approvals driving adoption of miniaturized extracorporeal life support devices in ambulatory care
- 5.7. Collaborations between medical device and software firms for integrated ECMO digital monitoring platforms
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Extracorporeal Membrane Oxygenation Machine Market, by Device Type
- 8.1. Veno Arterial
- 8.2. Veno Venous
- 9. Extracorporeal Membrane Oxygenation Machine Market, by Component Type
- 9.1. Cannula
- 9.2. Controllers
- 9.3. Heat Exchangers
- 9.4. Oxygenators
- 9.5. Pumps
- 10. Extracorporeal Membrane Oxygenation Machine Market, by Patient Type
- 10.1. Adults
- 10.2. Infants
- 10.3. Pediatric
- 11. Extracorporeal Membrane Oxygenation Machine Market, by Application
- 11.1. Cardiac Support
- 11.1.1. Cardiogenic Shock
- 11.1.2. Post Cardiotomy
- 11.2. Extracorporeal Cardiopulmonary Resuscitation
- 11.3. Respiratory Support
- 12. Extracorporeal Membrane Oxygenation Machine Market, by End User
- 12.1. Ambulatory Surgical Centers
- 12.2. Hospitals
- 12.3. Specialty Clinics
- 13. Extracorporeal Membrane Oxygenation Machine Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Extracorporeal Membrane Oxygenation Machine Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Extracorporeal Membrane Oxygenation Machine Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Getinge AB
- 16.3.2. Medtronic plc
- 16.3.3. LivaNova PLC
- 16.3.4. Terumo Corporation
- 16.3.5. Fresenius Medical Care
- 16.3.6. Hemovent N.V.
- 16.3.7. Spectrum Medical (UK) Limited
- 16.3.8. B. Braun Melsungen AG
- 16.3.9. Baxter International Inc.
- 16.3.10. Abiomed, Inc.
- 16.3.11. Abbott Laboratories
- 16.3.12. MicroPort Scientific Corporation
- 16.3.13. Nipro Corporation
- 16.3.14. OriGen Biomedical, Inc.
- 16.3.15. CytoSorbents Corporation
- 16.3.16. Senko Medical Instrument Mfg. Co., Ltd.
- 16.3.17. Braile Biomedica
- 16.3.18. Spectrum Medical Ltd.
- 16.3.19. Inspira Technologies OXY B.H.N. Ltd.
- 16.3.20. Eurosets S.r.l.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
